The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

BACKGROUND: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA‐REG OUTCOME trial. Recent trials evidenced several cardio-renal benefits of EMPA in n...

Descripción completa

Detalles Bibliográficos
Autores principales: Quagliariello, Vincenzo, De Laurentiis, Michelino, Rea, Domenica, Barbieri, Antonio, Monti, Maria Gaia, Carbone, Andreina, Paccone, Andrea, Altucci, Lucia, Conte, Mariarosaria, Canale, Maria Laura, Botti, Gerardo, Maurea, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305868/
https://www.ncbi.nlm.nih.gov/pubmed/34301253
http://dx.doi.org/10.1186/s12933-021-01346-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305868/
https://www.ncbi.nlm.nih.gov/pubmed/34301253
http://dx.doi.org/10.1186/s12933-021-01346-y

Ejemplares similares